Luis Meza Contreras, MD
Cards
About
Research
Publications
2025
Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma
Jaime-Casas S, Barragan-Carrillo R, Zugman M, Shah K, Ebrahimi H, Mercier B, Castro D, Zang P, LeVee A, Yip W, Li X, Dizman N, Salgia N, Zengin Z, Meza L, Hsu J, Nguyen C, Chehrazi-Raffle A, Pal S, Tripathi A. Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma. Frontiers In Oncology 2025, 15: 1669526. PMID: 41127009, PMCID: PMC12537358, DOI: 10.3389/fonc.2025.1669526.Peer-Reviewed Original ResearchAdvanced urothelial carcinomaObjective-response rateAntibody-drug conjugatesPeripheral sensory neuropathyAdverse eventsUrothelial carcinomaTreatment landscapeAnti-HER2Sensory neuropathyAll-grade toxicitiesAnti-HER2 regimensGrade 3 AEsRate of adverse eventsPublished Clinical TrialsGastrointestinal (diarrheaCombination regimensCombination therapyEfficacy outcomesRetrospective studyCase reportEmbase databasesRegimensClinical trialsFull-text reviewCarcinoma27Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma
Mercier B, Govindarajan A, Hansen N, Byron S, Hegde A, Leskoske K, Chawla N, Meza L, Zengin Z, Barragan-Carrillo R, Ebrahimi H, Castro D, Jaime-Casas S, Zugman M, Dizman N, Hsu J, Chehrazi-Raffle A, Tripathi A, Salgia N, Pal S, Pirrotte P. 27Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma. The Oncologist 2025, 30: oyaf276.028. PMCID: PMC12509655, DOI: 10.1093/oncolo/oyaf276.028.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsRenal cell carcinomaNon-respondersTargeted therapyHumoral immune responseImmune responseSystemic therapyCell carcinomaTT cohortMetastatic renal cell carcinoma patientsAdoptive cell therapy strategiesImmune checkpoint inhibitor cohortImmune cell pathwaysImmunogenic tumor microenvironmentRECIST v1.1 criteriaAdaptive immune responsesCell therapy strategiesCheckpoint inhibitorsNeoantigen analysisComprehensive analysis of AS eventsPeptide neoantigensTumor microenvironmentClinical benefitSplicing analysisComprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma
Salgia N, Khan A, Aubrecht W, Twoey G, Chow J, Attwood K, Yu H, Chiello J, Hansen N, Wasik B, Mercier B, Ebrahimi H, Meza L, Maguire O, Mastri M, Whalen C, Minderman H, Pirrotte P, Byron S, Repasky E, Singh P, Bshara W, Wang J, McGray A, Abrams S, Xu B, Eng K, Long M, Pal S, Kauffman E, Muhitch J. Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma. Cancer Cell 2025, 43: 2014-2033.e9. PMID: 40780212, PMCID: PMC12338066, DOI: 10.1016/j.ccell.2025.07.010.Peer-Reviewed Original ResearchImmune checkpoint blockadeRenal cell carcinomaClear cell RCCCell carcinomaTumor typesImmune sensitizationTumor-infiltrating T cellsSarcomatoid renal cell carcinomaTumor immune profileTertiary lymphoid structuresAggressive tumor typeHumoral immune activityCheckpoint blockadeSarcomatoid featuresCell RCCCXCL13 expressionLymphoid structuresT cellsRCC tumorsImmune activationSingle-cell analysisTumorCarcinomaRCCSRCCLong-term clinical outcomes with nivolumab/ipilimumab with or without Clostridium butyricum MIYAIRI588 in metastatic renal cell carcinoma (mRCC): A randomized phase Ib clinical trial.
Zugman M, Ebrahimi H, Meza L, Barragan-Carrillo R, Li X, Llamas-Quitiquit M, Hsu J, Zengin Z, Castro D, Mercier B, Jaime-Casas S, Chehrazi-Raffle A, Trent J, Lee P, Takahashi M, Dorff T, Caporaso G, Lee K, Pal S, Dizman N. Long-term clinical outcomes with nivolumab/ipilimumab with or without Clostridium butyricum MIYAIRI588 in metastatic renal cell carcinoma (mRCC): A randomized phase Ib clinical trial. Journal Of Clinical Oncology 2025, 43: 4550-4550. DOI: 10.1200/jco.2025.43.16_suppl.4550.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalClinical outcomesOverall survivalMedian progression-free survivalRandomized phase I trialTime of data cutoffPhase Ib clinical trialLong-term follow-up dataLong-term clinical outcomesObjective response rateDisease control ratePhase I trialRenal cell carcinomaSystemic immune responsesNewly diagnosed patientsFollow-up dataImproving clinical outcomesMedian OSSarcomatoid histologyCell histologyData cutoffIntermediate/high riskCell carcinomaI trialGenomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).
Ebrahimi H, Barragan-Carrillo R, Zugman M, Jaime-Casas S, Shah K, Castro D, Mercier B, Zengin Z, Meza L, Li X, Hsu J, Zang P, Dizman N, Nguyen C, Tripathi A, Dorff T, Pal S, Chehrazi-Raffle A. Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS). Journal Of Clinical Oncology 2025, 43: 5087-5087. DOI: 10.1200/jco.2025.43.16_suppl.5087.Peer-Reviewed Original ResearchNeuroendocrine prostate cancerTumor mutational burdenClinical characteristicsProstate cancerAggressive variant prostate cancerPrevalence of genomic alterationsHigh tumor mutational burdenClinical characteristics of patientsAndrogen receptor inhibitorsPersonalized treatment approachesFisher's exact testCharacteristics of patientsMicrosatellite instability-highIndividuals aged >Mutational burdenPathological confirmationPTEN alterationsReceptor inhibitorsNo significant differenceAggressive subtypeGenomic surrogateExact testGenomic alterationsClinical trialsTwo-proportion z-testComparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma
Jaime-Casas S, Chawla N, Salgia N, Mercier B, Govindarajan A, Li X, Castro D, Ebrahimi H, Barragan-Carrillo R, Zang P, LeVee A, Zugman M, Dizman N, Hsu J, Meza L, Zengin Z, Chehrazi-Raffle A, Dorff T, Pal S, Tripathi A. Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma. JCO Precision Oncology 2025, 9: e2400947. PMID: 40209138, DOI: 10.1200/po-24-00947.Peer-Reviewed Original ResearchConceptsSmall cell bladder cancerSmall cell lung cancerUrothelial carcinomaGenomic alterationsBladder cancerSmall cell lung cancer patientsSmall cell lung carcinomaSmall cell carcinomaRare histologic variantCell lung carcinomaAggressive disease courseCell lung cancerPathogenic genomic alterationsImproving clinical outcomesTreated with approachesHistological variantsCell carcinomaHistological groupsLung carcinomaClinical outcomesPoor outcomeRetrospective natureDisease courseLung cancerGenomic profilingEligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion
Mercier B, Govindarajan A, Castro D, Li X, Philip E, Feng M, Prajapati S, Chan E, Lee K, Sehgal I, Patel J, O'Dell A, Chehrazi‐Raffle A, Ebrahimi H, Rock A, Zengin Z, Meza L, Dizman N, Hsu J, Liu S, Dorff T, Pal S, Tripathi A. Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion. Cancer Medicine 2025, 14: e70696. PMID: 40145383, PMCID: PMC11947756, DOI: 10.1002/cam4.70696.Peer-Reviewed Original ResearchConceptsHepatitis B/C infectionHIV infectionClinical trialsConcurrent malignancyBrain metastasesVariant histologyEligibility criteriaPresence of brain metastasesAmerican Society of Clinical OncologyMetastatic urothelial cancerFisher's exact testType of therapyContemporary clinical trialsFriends of Cancer ResearchInclusion of patientsUrothelial cancerExact testClinical OncologyTherapy efficacyCancer clinical trialsCancer trialsHIVPatientsExclusion criteriaInfectionImpact of Insurance Status on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
Castro D, Gebrael G, Meza L, Li X, Tripathi N, Tandar C, Sayegh N, Zengin Z, Chehrazi-Raffle A, Govindarajan A, Dizman N, Barragan-Carrillo R, Ebrahimi H, Mercier B, Chawla N, Jaime-Casas S, Salgia N, Zugman M, Hsu J, Philip E, Bergerot C, Agarwal N, Pal S. Impact of Insurance Status on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. JCO Oncology Advances 2025 DOI: 10.1200/oa.24.00015.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalImpact of insurance statusOverall survivalRenal cell carcinomaSurvival outcomesCell carcinomaAssociated with significantly better PFSAssociated with significantly better survival outcomesAssociated with better progression-free survivalInsurance statusFirst-line systemic therapyMedicaid/no insuranceBetter survival outcomesKaplan-Meier methodLog-rank testAssociated with lower riskSystemic therapyPrimary insurance typeNo significant differenceNational Cancer Institute-designated cancer centerInstitutional databasePrivate insuranceCancer CenterLow riskCabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.
Ebrahimi H, Meza L, Dizman N, Barragan-Carrillo R, Li X, Llamas-Quitiquit M, Hsu J, Zengin Z, Castro D, Mercier B, Zugman M, Jaime-Casas S, Chehrazi-Raffle A, Trent J, Lee P, Takahashi M, Dorff T, Caporaso G, Lee K, Pal S. Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study. Journal Of Clinical Oncology 2025, 43: 543-543. DOI: 10.1200/jco.2025.43.5_suppl.543.Peer-Reviewed Original ResearchProgression-free survivalTreatment-related adverse eventsClinical benefitControl armTreatment armsFollow-upImproving progression-free survivalMedian progression-free survivalMetastatic renal cell carcinomaTime of data cutoffTarget lesion sizeTreatment naive patientsMedian Follow-UpPhase I studyKaplan-Meier methodSecondary clinical endpointsRenal cell carcinomaKarnofsky performance statusFisher's exact testMedian OSSarcomatoid featuresStable diseaseComplete responseData cutoffPapillary histologyEfficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials.
Jaime-Casas S, Zugman M, Barragan-Carrillo R, Zang P, Ebrahimi H, Mercier B, Castro D, Yip W, Li X, Dizman N, Salgia N, Hsu J, Nguyen C, Chehrazi-Raffle A, Zengin Z, Meza L, Pal S, Tripathi A. Efficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials. Journal Of Clinical Oncology 2025, 43: 813-813. DOI: 10.1200/jco.2025.43.5_suppl.813.Peer-Reviewed Original ResearchAny-grade adverse eventsAdvanced urothelial carcinomaObjective-response rateAntibody-drug conjugatesCombination regimensClinical trialsCheckpoint inhibitorsSafety/tolerability profileCombination therapyPublished prospective clinical trialsProspective clinical trialPeer-reviewed clinical trialsSystematic review of clinical trialsReview of clinical trialsRandom-effects modelEnfortumab vedotinSacituzumab govitecanUrothelial carcinomaProspective trialsTreatment landscapeMaculopapular rashEfficacy outcomesRetrospective studyToxicity profileCase report